Mda mb 453

Human breast cancer cell lines (MDA-MB-231 and MCF7) and NSCLC cell lines (H460 and H226B cells) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) or kindly provided by Dr. John V. Heymach (MD Anderson Cancer Center, Houston, TX, USA). T47D cells were kindly provided by Dr. Sang Kook Lee (Seoul National University, Seoul, Korea). MDA-MB-453, BT-20, and MDB-MB-468 cells were kindly provided by Dr. Hyeong-Gon Moon (Seoul National University, Seoul, Korea). The cells were cultured in DMEM (MDA-MB-231, MCF7, MDA-MB-453, and MDA-MB-468 cells) or RPMI 1640 medium (H460, H226B, T47D, and BT-20 cells) supplemented with 10% fetal bovine serum (FBS) and antibiotics (Welgene, Kyeongsan-si, Korea), and maintained at 37 °C with 5% CO₂ in a humidified atmosphere. Paclitaxel-resistant MDA-MB-231 (MDA/R) cells were generated by continuously exposing the cells to increasing concentrations of paclitaxel for more than 6 months. These cancer cell lines were authenticated and validated using an AmplFLSTR identifier PCR Amplification kit (Applied Biosystems, Foster, CA, USA; cat. no. 4322288) in 2013 and 2017. We used cell lines passed for fewer than three months.

A431 (human epidermoid carcinoma), A549 (human lung carcinoma), and MDA-MB-453 (human breast carcinoma) were obtained from the American Type Culture Collection (ATCC). A431, A549, and MDA-MB-453 cells were maintained in DMEM (Welgene Inc., Gyeongsan, Republic of Korea), RPMI-1640 (Welgene), and Leibovitz L-15 (Welgene), respectively. Media were supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA), 100 IU/mL penicillin (Gibco), and 100 μg/mL streptomycin (Gibco). The cells were cultured in a humidified atmosphere of 95% air and 5% CO₂ at 37 °C, but CO₂-free in the case of Leibovitz L-15.